Low serum salivary amylase levels have been associated with a range of metabolic abnormalities, including obesity and insulin resistance. We recently suggested that low copy-number at the AMY1 gene, associated with lower enzyme levels, also increases susceptibility to obesity. To advance our understanding of the effect of AMY1 copy-number variation on metabolism, we compared the metabolomic signatures of high and low copy-number carriers. We analysed, using mass spectrometry and NMR, the sera of healthy normal-weight women carrying either low (LA:≤4 copies; n=50) or high (HA:≥8 copies; n=50) AMY1 copies. Best fitting multivariate models (empirical P<1x10 -3 ) of MS and NMR data were concordant in showing differences in lipid metabolism between the two groups. In particular, LA carriers showed lower levels of long-and medium-chain fatty acids, and higher levels of dicarboxylic fatty acids and 2-hydroxybutyrate (known marker of glucose malabsorption). Taken together, these observations suggest increased metabolic reliance on fatty acids in LA carriers through β-and ω-oxidation and reduced cellular glucose uptake with consequent diversion of acetyl-CoA into ketogenesis. Our observations are in line with previously-reported delayed glucose uptake in LA carriers after starch consumption. Further functional studies are needed to extrapolate from our findings to implications for biochemical pathways.
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Abstract Low serum salivary amylase levels have been associated with a range of metabolic abnormalities, including obesity and insulin resistance. We recently suggested that low copy-number at the AMY1 gene, associated with lower enzyme levels, also increases susceptibility to obesity. To advance our understanding of the effect of AMY1 copy-number variation on metabolism, we compared the metabolomic signatures of high and low copy-number carriers. We analysed, using mass spectrometry and NMR, the sera of healthy normal-weight women carrying either low (LA:≤4 copies; n=50) or high (HA:≥8 copies; n=50) AMY1 copies. Best fitting multivariate models (empirical P<1x10 -3 ) of MS and NMR data were concordant in showing differences in lipid metabolism between the two groups. In particular, LA carriers showed lower levels of long-and medium-chain fatty acids, and higher levels of dicarboxylic fatty acids and 2-hydroxybutyrate (known marker of glucose malabsorption). Taken together, these observations suggest increased metabolic reliance on fatty acids in LA carriers through β-and ω-oxidation and reduced cellular glucose uptake with consequent diversion of acetyl-CoA into ketogenesis. Our observations are in line with previously-reported delayed glucose uptake in LA carriers after starch consumption. Further functional studies are needed to extrapolate from our findings to implications for biochemical pathways.
Salivary α-amylase (sAA), encoded by the AMY1 gene, is produced under the control of the autonomic nervous system by the salivary glands. It initiates starch digestion in the mouth, yielding a mixture of maltose, isomaltose and glucose. Therefore, it was expected that individuals with high levels of sAA would show higher postprandial glycaemia, compared to low sAA counterparts. A recent study showed, surprisingly, the opposite effect (1) . Lower serum amylase levels have been associated with susceptibility to metabolic abnormalities, including non-alcoholic fatty liver disease, obesity, and diabetes (2) (3) (4) .
Salivary amylase level is strongly correlated with the copy-number (CN) at the AMY1 gene (5).
Higher AMY1 copy-number and sAA protein levels were observed in populations traditionally consuming starch-rich diets compared to those consuming a low-starch diet (5) . We recently confirmed AMY1 gene expression and protein levels in serum to be inversely correlated with obesity and suggested CN variation at AMY1 to be an important driver of this relationship, showing association between low amylase CN and increased BMI and obesity risk in both adults (6) and children (7) . On the other hand, a novel study has suggested that CNV might not be the main factor driving the association between amylase levels and obesity susceptibility (8) . The mechanisms by which sAA contributes to an increased risk of metabolic diseases remain elusive (8, 9) . To further investigate the role of genetic variation at the AMY1 gene on the metabolism, we used untargeted 1 H-Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS)-based metabolomics, and compared the metabolomic profiles of a carefully selected sample of 100 healthy and normal-weight, age-matched women carrying either low or high AMY1 CN.
RESEARCH DESIGN AND METHODS

Study population and design.
Only women were included to provide a more homogenous study population to maximize power, given our small study population. The characteristics of the women carrying high (HA;n=50) or low (LA;n=50) copies of the AMY1 gene are shown in Table S1 . The women were selected from the prospective D.E.S.I.R. cohort (9) from among those for whom data on the inferred CN at the AMY1 gene were already available (6) . To
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control for the effects of potential confounders, we carefully selected two subsamples from the top and bottom 20% of the CN distribution (≤4; ≥8 CN). Exclusion criteria included: 1) BMI>25kg/m 2 or <18.5kg/m 2 ; 2) fasting glycaemia>6 mmol/l; 3) development of any metabolic disorders during 9-year follow-up period. Food and caloric intake were not significantly different between the HA and LA groups.
All participants signed a written informed consent and the study was approved by the Ethics
Committee for the Protection of Subjects for Biomedical Research of Bicêtre Hospital (France).
Serum amylase levels
Serum pancreatic and total amylase levels were measured by enzymatic colorimetric assays with an autoRoche/Hitachi cobas c701 (AMY-P-20766623322 and AMYL2-03183742122, Hoffman-La Roche). The sAA levels were obtained by subtracting the pancreatic amylase level from the total amylase level.
Mass spectrometry
MS-based metabolomics profiling was carried out at Metabolon (Durham, NC, USA). The processing and analysis of samples was performed as previously described (10) (Supplementary data).
H-Nuclear Magnetic Resonance
Spectra of serum samples were measured at 600.13 MHz on a Bruker Avance II 600-MHz spectrometer (Bruker BioSpin GmbH Rheinstetten, Germany) following Beckoner et al (11) . NMR spectra were phased and baseline corrected. Spectra were aligned using the CluPA algorithm (12) and the alanine signal used as reference (1.4784 ppm). Residue water signal was removed. Data were reduced to 513 bins by intelligent bucketing, and normalized by Total Sum Normalization. Mean centering and Pareto scaling were applied prior to performing the data analysis.
Identification of metabolomics signatures
We employed multivariate statistical data analyses based on projection methods. Principal Component Analysis (PCA) was used for the initial exploratory data analysis. Metabolomics signatures distinguishing
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HA and LA women were identified through Projection to Latent Structures Discriminant Analysis, based on VIP (Variable Importance in Projection) selection (PLS-DA VIP-based) (13) . Given the limited sample size, we used a careful and conservative approach to validate our results.
First, results were validated through N-fold full cross-validation, using different values of N (N=6,7,8;
we report only results for 7-fold as Q 2 and AUC CV -two measures to estimate the predictive ability of the model), as well as through 1,000 permutation testing on the HA/LA classes (13) .
Second, to avoid overfitting we performed stability selection by Monte-Carlo subsampling: real differences should be present consistently, and therefore should be found even under perturbation of the data by subsampling (14) . We generated 500 random datasets by Monte Carlo subsampling (with prior probability of 0.70), and then PLS-DA VIP-based was applied to each subsample, obtaining a set of 500 discriminant models. Each model was additionally validated by N-fold full cross-validation and 1,000
permutations of the class response. Metabolites discriminating between HA and LA were identified as those that were selected by >50% of all the models.
Both in the original and in the randomly generated datasets, the VIP threshold for the selection of metabolites discriminating between HA and LA classes was determined by maximising Q 2 , while the number of latent variables of the PLS model was calculated by maximising Q 2 under the constraint to pass the permutation test. To clarify model interpretation, PLS-DA VIP-based models were post-transformed into the equivalent Orthogonal-PLS-DA models (OPLS-DA) where the predictive and the orthogonal part of the models were identified.
RESULTS
Serum amylase levels
HA subjects showed significantly higher levels of serum sAA compared to LA counterparts (Wilcoxon
P=6.04×10 -8 ).
A smaller difference was detected for the pancreatic amylase levels (Wilcoxon P=0.025), which is likely to be a reflection of both physiological and structural correlations between the two enzymes (15) (Table S1; Figure S1 ).
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Model Fitting and Validation
The analysis of the NMR and MS datasets by PCA detected the presence of 15 outliers that were excluded from further analysis. The major patterns within the original data were captured by a small number of components, three for both NMR and MS datasets. The score scatter plots in Figure 1A Since the VIP and the correlation coefficient estimate the strength and the direction of the effect respectively, metabolites in the right quadrant of the plot showed higher levels in the HA group, while those in the left quadrant higher levels in the LA group (Figures 2A-2B ).
Metabolites from MS data were mapped into the Ingenuity Pathway Analysis Knowledge Base BMI was independent of HA/LA group definition and did not have any effect on the multivariable PLS models (r 2 <0.01; P>0.20). We further excluded association between BMI and each single discriminant metabolite through linear regression considering both BMI and HA/LA level as independent variables (P for BMI>0.10).
DISCUSSION
In this study we aimed to explore the effect of copy-number variation at AMY1 on metabolism by comparing the metabolomic signature in carefully matched healthy women, carrying low or high CN at the AMY1 gene as reflected in a significant difference in enzyme levels between the two groups (P=6.04×10-8) (fig. S1 ).
While this study design facilitates the identification of discriminant metabolites associated with AMY1 CN, results might be affected by spectrum bias as women were selected from the two ends of the CN distribution.
The best fitting models (empirical P<1x10 -3 ) identified through multivariate analyses of the MS and
women. Analysis of the MS discriminant metabolites using the Ingenuity Knowledge Base annotations confirmed the significant enrichment of functional categories for "Lipid metabolism", "Energy production", and "Carbohydrate metabolism". In particular, the MS data showed that the levels of four DFAs, suberate, sebacate, azelate, and dodecanedioate, were higher in the sera from LA women compared to HA (Table 2 ).
This increase in DFAs levels is suggestive of an upregulation of the ω-oxidation. In normal conditions, ω-oxidation plays a minor role in overall FAs oxidation. However, in certain physiological states, where mitochondrial β-oxidation is blocked or overwhelmed, free FAs are ω-oxidized in the reticulum, by a CYP-4A dependent pathway, to DFAs (16), which can then enter mitochondrial β-oxidation.
To corroborate the proposed interpretation, alongside the increase in DFAs, women with LA also showed lower serum concentrations of several medium and long chain fatty acids (Table 2 ). This reduction in FA levels is coherent with a more active uptake and oxidation, both via β-and ω-oxidation.
Interestingly, LA women also showed increased levels of 2-hydroxybutyrate, a biomarker for insulin resistance in humans (17) ( Table 2 ). Taken together, these results suggest a pattern of reduced cellular glucose uptake, and consistent metabolic shift toward lipid exploitation, in LA women. Interestingly, NMR suggested a slight increase of glucose levels in LA sera.
In a similar line, Mandel and colleagues (18) recently published an experiment where they measured the dynamics of postprandial glucose and insulin following controlled starch, or glucose meals in healthy LA and HA carriers. While LA and HA did not show any differences after the glucose-based meal, LA carriers showed significantly higher glucose levels following the starch-based meal, suggesting glucose malabsorption after starch ingestion in people with constitutionally low salivary amylase levels. Mandel et al advocated that this effect might be mediated by delayed preabsorptive insulin response in the LA group after the starch meal.
In summary, our results support the hypothesis that salivary α-amylase CN might play a role in glucose uptake, offering novel evidence to support further research on its mechanisms of action.
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Metabolite
For this metabolomics analysis, we aimed to select, among those with available AMY1 CNV data, two homogenous groups who differed only in the number of copies of the salivary amylase gene.
We reasoned that many factors including age, sex, and metabolic disease, may alter metabolite levels as identified through mass spectrophotometry and NMR,, that could therefore act as potential confounders in our study.
Starting with 2,137 people, we first selected those of normal weight (18.5 < BMI < 25 kg/m²; N=1,259), of whom 800 were women, with ages ranging from 30 to 65 years. We selected a younger subset of 280 women aged between 30 and 40 years. Of these, 60 had predicted AMY1 CN <=4 (LA) and 86 CN>=8 (HA) -which represent, respectively, the first and third quartile of the copy number distribution observed in this population. Availability of nine years of follow-up data in the D.E.S.I.R. cohort reduces the possibility that underlying (and undetected) predisposition to metabolic disorders was present in women belonging to the two selected groups, thus reducing potential confounding from factors that could have been disproportionately prevalent in one of the two genotype groups.
Fifty age-matched women were selected from each of the two LA/HA groups. No significant differences in self-reported food preference and intake nor sporting activity were detected between the two groups.
Finally, serum salivary amylase levels were used to validate the genetic data and verify whether low and high copy number at AMY1 was also reflected in high and low serum amylase levels.
MASS SPECTROMETRY
The metabolon analytical platform consisted of two separate ultra-high performance liquid chromatography/tandem mass spectrometry devices (UHPLC/MS/MS 2 ), optimized one for basic and acidic species, and one for GC/MS. Each sample was run simultaneously on the 3 analytic machines. 
TABLES
